14 June 2021
Published in Rheumatology, our new CME-accredited supplement explores the future of JAK1 selective inhibitors.
What does the supplement cover?
This supplement provides a comprehensive overview of the latest scientific and clinical data on JAK1 selective inhibitors. Starting with the key role of JAK1 selective inhibitors, the authors cover everything from the results of early phase studies of upadacitinib and filgotinib, to a review of existing safety data. Peter Nash’s examination of the clinical use of JAK1 inhibitors for rheumatoid arthritis may be of particular interest, or perhaps the summaries of current trial data for spondyloarthropathies and inflammatory bowel disease.
How do I earn CME credits?
We’re excited to announce that this is our first CME-accredited supplement. To receive a CME certificate of participation and up to 7.0 AMA PRA Category 1 Credits, you should read all of the papers in the supplement and complete the post-activity assessment. Details are available in the abstract of each supplement article.
Guest Editor Prof Christopher Edwards says: "JAK inhibitors have become such an important part of how we treat patients with inflammatory arthritis but there’s still lots to learn. It’s been a real pleasure reading the thoughts of world experts in the field who have shared their views on the importance of JAK1 selective inhibitors."
Explore the supplement here